贝达药业：12月15日召开董事会会议

Group 1 - The core point of the article is that Beida Pharmaceutical (SZ 300558) held its 29th meeting of the fourth board of directors on December 15, 2025, to review the proposal regarding the remuneration of independent directors for the fifth board [1] - For the year 2024, Beida Pharmaceutical's revenue composition is entirely from pharmaceutical manufacturing, accounting for 100.0% [1] - As of the time of reporting, Beida Pharmaceutical has a market capitalization of 19.6 billion yuan [1]